[The Staffs comment is noted, and the Company will include disclosure in Item 5 of its annual report on Form20-F for the year ending December31, 2011 regarding the need to accrue and pay withholding or other taxes if funds are repatriated and the Companys current plans with respect to repatriation of funds.]
[Company Contact FOR RELEASE ON NOVEMBER 7, 2011 AT 4:20 p.m. EST (New York) China Biologic Reports Third Quarter 2011 Results TAI'AN, Shandong Province, China, November 7, 2011 China Biologic Products, Inc. (NASDAQ: CBPO) (China Biologic or the Company), one of the leading plasma-based biopharmaceutical companies in the Peoples Republic of China (PRC), today reported its financial results for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): November 7, 2011 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or former address, if changed]
[The Staffs comment is noted, and the Company will include disclosure in Item 5 of its annual report on Form20-F for the year ending December31, 2011 regarding the need to accrue and pay withholding or other taxes if funds are repatriated and the Companys current plans with respect to repatriation of funds.]
[Company Contact FOR RELEASE ON NOVEMBER 7, 2011 AT 4:20 p.m. EST (New York) China Biologic Reports Third Quarter 2011 Results TAI'AN, Shandong Province, China, November 7, 2011 China Biologic Products, Inc. (NASDAQ: CBPO) (China Biologic or the Company), one of the leading plasma-based biopharmaceutical companies in the Peoples Republic of China (PRC), today reported its financial results for] [FORM 8-K CURRENT REPORT Date of Report (Date of Earliest event Reported): November 7, 2011 CHINA BIOLOGIC PRODUCTS, INC. Delaware 001-34566 75-2308816 (State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization) No. 14 East Hushan Road, Tai'an City, Shandong, 271000 People's Republic of China 86-538 -620-2306 ____________________________________________________________ (Former name or former address, if changed]
[Mindray Announces Third Quarter 2011 Financial Results Shenzhen, China November7, 2011 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter ended September30, 2011. Highlights for Third Quarter 2011 - Net revenues were $218.4 million, up 29.8% over] [Mindray Announces Up to $100 Million Share Repurchase Program Shenzhen, China November7, 2011 Mindray Medical International Limited (Mindray ormpany, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that its Board of Directors has approved a share repurchase program. The share repurchase program is authorized to be in effect through]
[FORM 10-Q (Mark One) For the quarterly period ended: September 30, 2011 For the transition period from ____________ to _____________ CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) No. 14 East Hushan Road Taian City, Shandong 271000 Peoples Republic of China (+86) 538-620-2306 _____________________________________________________ Yes [X] No [ ] Yes] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Y. Tristan Kuo, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. (Principal Financial Officer)]
[FORM 10-Q (Mark One) For the quarterly period ended: September 30, 2011 For the transition period from ____________ to _____________ CHINA BIOLOGIC PRODUCTS, INC. Delaware 75-2308816 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) No. 14 East Hushan Road Taian City, Shandong 271000 Peoples Republic of China (+86) 538-620-2306 _____________________________________________________ Yes [X] No [ ] Yes] [CERTIFICATIONS I, Chao Ming Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Y. Tristan Kuo, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. (Principal Financial Officer)]
[ATA Reports Fiscal 2012 Second Quarter Financial Results and Company to Hold Conference Call on November 7 at 8 a.m. ET ATA Inc. (ATA or the Company, Nasdaq: ATAI) Beijing, China, November 4, 2011 (NY) / November 5, 2011 (China) Second Quarter 2012 Financial and Operating Highlights Net revenues of RMB70.4 million (US$11.0 million), up 111.7% year over] [FORM 6-K November 7, 2011 ATA Inc. 8th Floor, Tower E x x n/a ATA Inc. Benson Tsang Benson Tsang Chief Financial Officer Description 99.1 6-K 1 htm_6254.htm LIVE FILING]
